Stocks · News reference

Why Is Belite Bio Stock Soaring Friday?

Sep 4, 2026, 5:41 PMVandana Singh

Canaccord Genuity initiates Belite Bio (BLTE) with a Buy and $303 target on FDA Priority Review for tinlarebant.

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Sep 4, 2026, 5:41 PM
Checked: Sep 4, 2026, 5:41 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaSep 4, 2026, 2:04 PMBenzinga Newsdesk
Belite Bio shares are trading higher after Canaccord Genuity initiated coverage on the stock with a Buy rating and announced a $303 price target.
BLTE
BenzingaSep 4, 2026, 1:10 PMAvi Kapoor
This PulteGroup Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday
Analysts initiated coverage: Hold on Lennar, Buys on Belite Bio, PulteGroup.
BLTE LEN PHM
BenzingaSep 4, 2026, 12:06 PMBenzinga Newsdesk
Canaccord Genuity Initiates Coverage On Belite Bio with Buy Rating, Announces Price Target of $303
Canaccord Genuity analyst Whitney Ijem initiates coverage on Belite Bio (NASDAQ:BLTE) with a Buy rating and announces Price Target of $303.
BLTE